An Open-Label, Multi-Center, Prospective, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery for Hypertrophic Scars in Healthy Adults
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 May 2017
At a glance
- Drugs RXI 109 (Primary)
- Indications Hypertrophic scars
- Focus Therapeutic Use
- Sponsors RXi Pharmaceuticals
- 11 May 2017 According to a RXi Pharmaceuticals media release, the company will provide a full read-out, for Cohorts 3 and 4, in the second half of 2017.
- 06 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Aug 2017.
- 11 Aug 2016 According to a RXi Pharmaceuticals media release, company is evaluating the best treatment length (Cohorts 3 and 4) and anticipates preliminary data in the second half of 2016 with a full interim analysis, for Cohorts 3 and 4, mid-2017.